Evidence map›Paper›PMID 24466350›Full record

ArticlePloS one2014

The RhoGAP activity of myosin IXB is critical for osteoclast podosome patterning, motility, and resorptive capacity.

Brooke K McMichael, Katharine F Scherer, Nicole C Franklin, Beth S Lee

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 32 citations in OpenAlex.

  1. Review
  2. Review
  3. Myosin IXB protects immune cells from virus infection.The Journal of general virology · 2025
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Non-canonical Wnt signals regulate cytoskeletal remodeling in osteoclasts.Cellular and molecular life sciences : CMLS · 2018
    Review
  13. Article
  14. Tools of the trade: podosomes as multipurpose organelles of monocytic cells.Cellular and molecular life sciences : CMLS · 2015
    Review
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Brooke K McMichaelDepartment of Physiology and Cell Biology, The Ohio State University College of Medicine, Columbus, Ohio, United States of America.
Katharine F SchererDepartment of Physiology and Cell Biology, The Ohio State University College of Medicine, Columbus, Ohio, United States of America.
Nicole C FranklinDepartment of Physiology and Cell Biology, The Ohio State University College of Medicine, Columbus, Ohio, United States of America.
Beth S LeeDepartment of Physiology and Cell Biology, The Ohio State University College of Medicine, Columbus, Ohio, United States of America.
The Ohio State University · US

Funding

DYNAMICS OF THE ACTIN CYTOSKELETON IN OSTEOCLASTSR01AR051515 · NIAMS · OHIO STATE UNIVERSITY · PI LEE, BETH S. · 2006 to 2009
$1.0M
NIAMS NIH HHS R01 AR051515
6 · The paper itself

Abstract

Osteoclasts are large, multinucleated cells of the monocyte-macrophage lineage that generate specialized substrate adhesion complexes to facilitate their function as bone-degrading cells. The patterning and function of these actin-based complexes, podosomes and sealing zones, are regulated by the small GTPase Rho. Myosin IXB (Myo9b) is a unique actin-based motor protein that contains a RhoGAP domain, which, like other RhoGAPs, is inhibitory to Rho signaling. In this study, Myo9b is shown to be expressed in osteoclasts and act as a critical regulator of podosome patterning and osteoclast function. SiRNA-mediated knockdown of Myo9b results in increased activity of Rho but not Rac in osteoclasts. Knockdown in osteoclasts on glass results in altered podosome patterning and decreased motility, and this effect is reversed by addition of a Rho inhibitor. SiRNA-mediated suppression of Myo9b expression in osteoclasts on bone results in a dramatic loss of resorptive capacity even though sealing zones appear normal. This loss of resorption is also reversible with addition of a Rho inhibitor. Cells with diminished Myo9b levels display mislocalization and suppressed activation of Src, a tyrosine kinase with critical effects on osteoclast actin cytoskeletal rearrangement and function. In addition, siRNA-treated cells display poorly formed microtubule networks and a lack of tubulin acetylation, a marker of microtubule stability. However, short-term addition of TNFα to cells with suppressed Myo9b levels overcomes or circumvents these defects and causes increased sealing zone size and resorptive capacity. These results indicate that the RhoGAP activity of Myo9b plays a key role in regulating the actin-based structures necessary for osteoclast motility and resorption, and confirms that Myo9b can act as a motorized signaling molecule that links Rho signaling to the dynamic actin cytoskeleton.

Indexed as

ActinsAnimalsBlotting, WesternBone ResorptionCell Adhesion MoleculesCell MovementImmunohistochemistryIndolesMiceMicroscopy, ConfocalMultiprotein ComplexesMyosinsOsteoclastsRNA InterferenceActinsCell Adhesion MoleculesDAPIIndolesMultiprotein Complexesmyosin IXBMyosins

Identifiers

PMID24466350
PMCPMC3900720
OpenAlexW2052381990

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.